000			03711nam a22004575i 4500
999			_c200457105 _d75317
003			TR-AnTOB
005			20231109085746.0
007			cr nn 008mamaa
008			221118s2022 sz | s |||| 0|eng d
020			_a9783031113635
024	7		_a10.1007/978-3-031-11363-5 _2doi
040			_aTR-AnTOB _beng _erda _cTR-AnTOB
041			_aeng
060			_aWC 100
072		7	_aMJ _2bicssc
072		7	_aMED045000 _2bisacsh
072		7	_aMJ _2thema
096			_aWC100EBK
245	1	0	_aInfectious Complications in Biologic and Targeted Therapies _h[electronic resource] / _cedited by Carlos Cervera, Jose Maria Aguado.
250			_a1st ed. 2022.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2022.
300			_a1 online resource
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aOverview on the risk of infection associated with biologic and targeted therapies -- Timeline of infections associated with biologic and targeted therapies -- Infectious disease evaluation of candidates to new therapies -- Vaccines and biologic and targeted therapies -- Travel and risk of infections -- Anti-necrosis tumoral factor-alpha agents -- CD19-targeted agents -- CD20-targeted agents -- CD22-targeted agents -- CD30-targeted agents -- CD33 and CD38-targeted agents -- CD40 and CD319-targeted agents -- CD52-targeted agents -- CCR4-targeted agents -- Cell-surface receptors I: VEFG targeted agents -- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents -- Interleukin-1 targeted agents -- Interleukin-5 and interleukin-6 targeted agents -- Interleukin-12/23 p40 targeted agents -- Sphingosine-1 phosphate receptor modulators -- Immune checkpoint inhibitors -- α4-integrin-targeted agents -- Tyrosin-kinase inhibitors -- Bcl-2, JAK and mTOR inhibitors -- Infections associated with the use of CarT cells -- Pulmonary infiltrates -- Tuberculosis -- Cytomegalovirus and other herpesviruses -- Invasive fungal infections -- Progressive multifocal leukoencephalopathy -- Hepatitis virus.
520			_aThis book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.
650		0	_aInternal medicine.
650	1	4	_aInternal Medicine.
653		0	_aCommunicable Diseases -- drug therapy
700	1		_aCervera, Carlos. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aAguado, Jose Maria. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
856	4	0	_uhttps://doi.org/10.1007/978-3-031-11363-5 _3Springer eBooks _zOnline access link to the resource
942			_2NLM _cEBK